Vimarsana
Biggest News Aggregation in the World

Page 21 - Jeff Mclaughlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeff Mclaughlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeff Mclaughlin Today - Breaking & Trending Today

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: GSK shares positive Phase III data for daprodustat - Vimarsana News

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: GSK shares positive Phase III data for daprodustat

Investegate announcements from GlaxoSmithKline PLC, GSK shares positive Phase III data for daprodustat

GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease - Vimarsana News

GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease

/PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in Chronic Kidney Disease:...

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings - Vimarsana News

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings

The CARISEL study showed most people living with HIV who started treatment felt positive about the long-acting regimen, a sentiment shared by healthcare teams For media and investors only ViiV

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV - Vimarsana News

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Healthcare professionals and people living with HIV now have the choice of starting long-acting treatment with the oral initiation phase or starting injections directly For media and investors only ViiV

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: Directorate Change - Vimarsana News

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: Directorate Change

Investegate announcements from GlaxoSmithKline PLC, Directorate Change